<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00101361</url>
  </required_header>
  <id_info>
    <org_study_id>535</org_study_id>
    <nct_id>NCT00101361</nct_id>
  </id_info>
  <brief_title>Oxandrolone to Heal Pressure Ulcers</brief_title>
  <official_title>CSP #535 - Anabolic Steroid Therapy on Pressure Ulcer Healing in Persons With Spinal Cord Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to determine whether the use of oxandrolone, an anabolic steroid, can
      heal pressure ulcers in persons with spinal cord injury (SCI). In a Feasibility Study, three
      VA SCI Units will screen and randomize patients into treatment with oxandrolone or with
      placebo. Eleven other sites will screen patients to determine eligibility but will not treat
      patients with the agent. Following the Feasibility Study, all sites will participate in a
      blinded, randomized treatment study. A total of 400 patients will be enrolled over a
      four-year period. Any patient in a participating unit who has chronic SCI and a
      difficult-to-heal pelvic ulcer will be eligible for the study if other entry criteria are
      met. All enrolled patients will be followed for a period of 24 weeks to determine whether
      their target pressure ulcers heal. Those who are healed will be followed for an additional
      four weeks to determine whether the ulcer remains healed.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to determine whether SCI inpatients with a chronic Stage III or IV
      pressure ulcer of the pelvic region who are randomized to receive 24 weeks of optimized
      clinical care and an oral anabolic steroid agent (oxandrolone) will have a greater percent of
      healed pressure ulcers than those who receive placebo and the same optimized clinical care.
      The major secondary objective is to determine whether the healed pressure ulcer will remain
      healed for at least 8 weeks.

      Subjects are registered into a 4 week screening phase to be followed with weekly photos of
      the ulcer and if healed less than 30% (from the day 1 photo to the day 28 photo) with
      standard clinical care, they are introduced to the treatment phase (randomized) and followed
      for another 24 weeks on either oxandrolone or placebo. Wounds that heal (remain closed for at
      least 96 hours) are then subject to 2 four week follow up visits.

      Criteria for entering the screening phase are simple: either gender, age 18 years or older,
      inpatient with SCI or equivalent spinal cord damage and at least 1 Stage III or IV
      (indicating a severe wound, &lt;260cm2) pressure ulcer of the pelvic region.

      September 2006 - year one report submitted and approved by Central Office. Plan to add up to
      3 more sites in the next year.

      January 2007 - site #16 (San Antonio) is approved by Veterans Affairs Cooperative Studies
      Program Central Office to be invited.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    futility analysis showed low probability of detecting a significant difference
  </why_stopped>
  <start_date>August 2005</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>A Healed Pressure Ulcer</measure>
    <time_frame>healing was measured from randomization to full healing or 24 weeks, whichever occured first.</time_frame>
    <description>Patients remained in treatment until full healing of the target pressure ulcer (defined as re-epithelialization to a cicatrix with a dry surface and zero open area for a minimum of 96 hours) or 24 weeks, whichever occured first.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">212</enrollment>
  <condition>Pressure Ulcer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oxandrolone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxandrolone</intervention_name>
    <description>Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        SCREENING PHASE:

          1. Male or female inpatient with SCI or equivalent spinal cord damage.

          2. At least one Stage III or IV (including a severe wound, &lt;260cm2) pressure ulcer of the
             pelvic region.

        TREATMENT PHASE:

        1. documentation (through screening phase) of difficult to heal (defined as &lt;30% area
        reduction) or worsening status of the pressure ulcer for at least 28 days as inpatient
        (screening phase)

        Exclusion Criteria:

        SCREENING PHASE:

          1. Persons who are candidates for and elect to have reconstructive flap surgery of the
             TPU;

          2. Persons with known osteomyelitis who have not been, or refuse to be, adequately
             treated with appropriate antibiotic treatment for at least 6 weeks and/or appropriate
             surgical procedures, as determined by the patients' physician, as well as patients who
             have not had resolution of osteomyelitis after 3 months of antibiotic and/or surgical
             care.

          3. Psychopathology (documentation in the medical record or history of self-abusive
             behavior specific to pressure ulcer healing which may or may not include major or
             minor psychiatric illness) that may conflict with study objectives;

          4. Previously diagnosed active malignant disease;

          5. Suspicion of skin cancer at the pressure ulcer site (a biopsy-negative patient is not
             excluded, nor is a biopsy-positive patient excluded after a curative excision of the
             lesion);

          6. Radiation therapy in the pressure ulcer field at anytime during the patient's
             lifetime;

          7. Life expectancy less than 12 months;

          8. Nephrosis, hemodialysis or chronic ambulatory peritoneal dialysis therapy;

          9. AIDS patients at immunological risk of infectious complications defined as any of the
             following: (1) CD4 count &lt;100 cells/ L or (2) CD4 count 100 to 200 cells/ L and WBC &lt;
             4,000 cells/ L or (3) a confirmed viral load within the past 6 months;

         10. Administration of oxandrolone or another anabolic agent (not including testosterone
             replacement therapy) within the past 6 months;

         11. A known hypersensitivity to anabolic steroid medications (specifically oxandrolone);

         12. Coronary athersclerosis with unstable angina pectoris or a history within the past 3
             months of an acute myocardial event or decompensated congestive heart failure.

         13. Inability or unwillingness of the subject or surrogate to provide informed consent.

        TREATMENT PHASE:

          1. TPU &gt;200 cm2 surface area of the pelvic region

          2. Pressure ulcers with a clinical impression that are not expected to heal, such as
             those with: osteomyelitis (defined as persons with known osteomyelitis who have not
             been, or refuse to be, adequately treated with appropriate antibiotic treatment for at
             least 6 weeks and/or appropriate surgical procedures, as determined by the patients'
             physician, as well as patients who have not had resolution of osteomyelitis after 3
             months of antibiotic and/or surgical care), sinus tracts suggestive of active
             osteomyelitis, communication to the synovial space, or other conditions;

          3. Patient had flap surgery of the TPU during the Screening Phase;

          4. Multiple full-thickness pressure ulcers that have a body surface area totaling
             &gt;500cm2;

          5. Clinical and/or laboratory evidence suggestive of prostate cancer;

          6. Elevated liver function tests (AST &gt;112 IU/L or bilirubin &gt;3mg/dl);

          7. Diabetes mellitus with less than optimal glycemic control (HbA1c &gt;8.0%);

          8. Received moderate (equivalent to prednisone 40 to 60 mg/d) or high dose (equivalent to
             prednisone &gt;60 mg/d) systemic corticosteroids for at least 4 weeks, immunosuppressive
             agents, anti-cancer agents, or any radiation therapy within 30 days prior to
             randomization or are likely to receive one of these therapies during study
             participation;

          9. Initiating or continuing therapy with appetite stimulants (e.g., Megase);

         10. Current pharmacological therapy for hepatitis B or C infection;

         11. Pregnancy or lactating female;

         12. Females of child-bearing potential who are unwilling to agree to abstinence from
             sexual intercourse or the use of two reliable forms of contraception during the study;
             males unwilling to agree to abstinence from sexual intercourse or use of a condom
             during the study;

         13. Expected use of oral anticoagulants (e.g. warfarin sodium) during the treatment phase;

         14. Hypercalcemia;

         15. Coronary athersclerosis with unstable angina pectoris or a history within the past 3
             months of an acute myocardial event or decompensated congestive heart failure;

         16. Participation in another active treatment clinical trial;

         17. Inability or unwillingness of the subject or surrogate to provide informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Bauman, MD</last_name>
    <role>Study Chair</role>
    <affiliation>VA Medical Center, Bronx</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Long Beach</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90822</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Palo Alto Health Care System</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94304-1290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA San Diego Healthcare System, San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>James A. Haley Veterans Hospital, Tampa</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Augusta</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edward Hines, Jr. VA Hospital</name>
      <address>
        <city>Hines</city>
        <state>Illinois</state>
        <zip>60141-5000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Boston Healthcare System, Brockton Campus</name>
      <address>
        <city>Brockton</city>
        <state>Massachusetts</state>
        <zip>02301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, St Louis</name>
      <address>
        <city>St Louis</city>
        <state>Missouri</state>
        <zip>63106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Bronx</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10468</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, Cleveland</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA North Texas Health Care System, Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michael E. DeBakey VA Medical Center (152)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hunter Holmes McGuire VA Medical Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23249</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zablocki VA Medical Center, Milwaukee</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53295-1000</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>VA Medical Center, San Juan</name>
      <address>
        <city>San Juan</city>
        <zip>00921</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 7, 2005</study_first_submitted>
  <study_first_submitted_qc>January 7, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2005</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>September 23, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>November 26, 2013</last_update_submitted>
  <last_update_submitted_qc>November 26, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>dermatologic</keyword>
  <keyword>skin</keyword>
  <keyword>clinical trial</keyword>
  <keyword>androgen/anabolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Pressure Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxandrolone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>enrollment started 08/01/2005 and ended 10/10/2008 at 15 VA Medical Centers. Subjects were randomized only after a four week screening phase.</recruitment_details>
      <pre_assignment_details>Potential participants were screened for four weeks to determine eligibility based on documentation of a difficult-to-heal or worsening status of the pressure ulcer as an inpatient.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>1 Oxandrolone</title>
          <description>oxandrolone - two 5mg capsules twice daily</description>
        </group>
        <group group_id="P2">
          <title>2 Placebo</title>
          <description>placebo - two capsules twice daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
                <participants group_id="P2" count="104"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>overall baseline participants were determined by number of participants that were eligible after screening based on a pressure ulcer that is defined as hard-to-heal or worsening at randomization.</population>
      <group_list>
        <group group_id="B1">
          <title>Oxandrolone</title>
          <description>Oxandrolone</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="108"/>
            <count group_id="B2" value="104"/>
            <count group_id="B3" value="212"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.4" spread="10.4"/>
                    <measurement group_id="B2" value="57.3" spread="11.6"/>
                    <measurement group_id="B3" value="57.9" spread="11.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="103"/>
                    <measurement group_id="B3" value="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Puerto Rico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>A Healed Pressure Ulcer</title>
        <description>Patients remained in treatment until full healing of the target pressure ulcer (defined as re-epithelialization to a cicatrix with a dry surface and zero open area for a minimum of 96 hours) or 24 weeks, whichever occured first.</description>
        <time_frame>healing was measured from randomization to full healing or 24 weeks, whichever occured first.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>1 Oxandrolone</title>
            <description>oxandrolone - two 5mg capsules twice daily</description>
          </group>
          <group group_id="O2">
            <title>2 Placebo</title>
            <description>placebo - two capsules twice daily</description>
          </group>
        </group_list>
        <measure>
          <title>A Healed Pressure Ulcer</title>
          <description>Patients remained in treatment until full healing of the target pressure ulcer (defined as re-epithelialization to a cicatrix with a dry surface and zero open area for a minimum of 96 hours) or 24 weeks, whichever occured first.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="104"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>For spinal cord injury patients with a Stage III or IV pressure ulcer of the pelvic region who receive 24 weeks or less of optimized clinical care (i.e., guideline-driven care with nutritional support) compared with optimized clinical care and an oral anabolic steroid agent (oxandrolone) there will be no difference in the percent of healed pressure ulcers.</groups_desc>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>the required sample size of 400 participants provided 85% power to detect an increase in healing from 25% in the placebo group to 40% in the oxandrolone group, as assuming a 0.05 (2-sided) type I error, 13% rate of loss to follow up, and a test of proportions by using an arcsine transformation.</non_inferiority_desc>
            <p_value>&lt;0.05</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-5.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.5</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>years, 5 months</time_frame>
      <desc>Adverse events were reported for each event not each subject, therefore participants could have one or more events. The total events as reported is expected to surpass the total participants. The total participants with at least one adverse event (AE) is 95 oxandrolone and 85 placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>1 Oxandrolone</title>
          <description>oxandrolone - two 5mg capsules twice daily</description>
        </group>
        <group group_id="E2">
          <title>2 Placebo</title>
          <description>placebo - two capsules twice daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MeDRA 13</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>small bowel obstruction, renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>oral cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="108"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>death</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="104"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>elective bladder stone removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="108"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>myocutaneous flap surgery</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MeDRA 13</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="95" subjects_at_risk="108"/>
                <counts group_id="E2" subjects_affected="85" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>constipation or diarrhea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>nausea / vomitting</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>infection</sub_title>
                <description>cellulitis, sepsis, clostridial</description>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>osteomylitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="108"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="108"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>urinary tract infection</sub_title>
                <counts group_id="E1" events="37" subjects_affected="37" subjects_at_risk="108"/>
                <counts group_id="E2" events="28" subjects_affected="28" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>fever</sub_title>
                <counts group_id="E1" events="17" subjects_affected="17" subjects_at_risk="108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>elevated liver enzyme levels</sub_title>
                <counts group_id="E1" events="35" subjects_affected="35" subjects_at_risk="108"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>non-Target Pressure Ulcer (TPU) skin ulcer</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="108"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="104"/>
              </event>
              <event>
                <sub_title>skin rash / complication</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="108"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="104"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Selection of severe wounds may have reduced treatment response. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between groups.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>William A. Bauman, M.D.</name_or_title>
      <organization>James J. Peters VA Medical Center</organization>
      <phone>718-584-9000</phone>
      <email>william.bauman@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

